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The beneficial effect of aspirin (ASA) in unstable angina is well established,
yet data on effect of ASA during the hyperacute phase of myocardial infarc-
tion (AMI) is limited. We evaluated the effect of early chewed ASA adminis-
tration on reperfusion rate and hospital outcome in 90 consecutive AMI pa-
tients treated at home or in the Emergency Room. All patients had ischemic
chest pain of :0:30 minutes, associated with :0:2 mm STt. Early reperfusion
within 30 minutes occurred in 42 patients (46.7%); only 3 patients needed
thrombolysis. In 27 controls reperfusion occurred in 7 patients (25.9%); p
= 0.05. No difference in hospital outcome was observed between patients
with ASA-induced reperfusion and patients treated by thrombolytics.
Conclusion: 1) Chewed ASA taken early in the hyperacute phase of AMI
induced sustained reperfusion in a significant number of patients (46.7%);
2) The above results call for on-scene early administration of chewed ASA in
all suspected AMI patients.
Pawel Buszman, Mariusz GasiDr, Andrzej Wnek, Zbigniew Kalarus,
Stanislaw Pasyk. Silesian Center of Cardiology, Zabrze, Poland
The aim of this study was to assess the influence of pre-hospital treatment
with intravenDus heparin on the early patency rate olthe infarct related artery
in acute myocardial infarction. The inclusion criteria were: beginning of chest
pain in the 6 hDurs preceding admission, ST segment elevation :0: 1 mm in at
least two leads of the standard ECG and no contraindications to antithrom-
botic treatment. One hundred and twenty four patients with these criteria
were divided into 2 groups. Forty five patients (group I) were treated with
5,000 units of heparin Lv. befDre admission tD hospital. Seventy nine patients
(group II) did not receive heparin before hospitalisation. All patients in both
groups were put on Aspirin 150 mg p.o., nitro-glycerine and analgesics be-
fore admission. The mean period from the beginning of the chest pain was
2.7 ± 1.5 hour in group I and 2.8 ± 1.4 hour in group II (p = NS). Both groups
did not differ in relation to age, sex, risk factors and previous incidence of
myocardial infarction. In the emergency room all patients were put on hep-
arin and nitro-glycerine infusions Lv. and were transferred immediately to the
catheterisation laboratory for cDronary angiography. The flow through the in-
farct related artery was assessed according to the TIM I classification. Patent
infarct related arteries (i.e. TIMI flow grade I, 2 or 3) were observed in 19 pa-
tients (42.2%) in group I and in 18 (22.8%) in group II (p = 0.038). Successful
reperfusion (defined as TIMI grade 2 Dr 3) was present in 11 patients (24.4%)
in group I and in 7 (8.8%) in group II (p = 0.035).
.TIMI2,3 CTIMIO,1I
This pilot study suggests that pre-hospital treatment with intravenous hep-
arin can significantly improve flow in infarct related arteries. A prospective
randomised study is needed to confirm these results.
Aspirin-induced Reperfusion in Acute Myocardial
Infarction
Arieh Freifeld, Babeth Rabinowitz, Elieser Kaplinsky, Michal Benderly,
Michael ScheinDwitz, Oren Agranat, Dov Freimark, Hanoch Hod. Heart Institute,
Sheba Medical Center, Tel-Hashomer, Israel
Influence of Pre-Hospital Heparinisation on Early
Patency Rate of Infarct Related Artery in Acute
Myocardial Infarction
We have previously shown that regional myocardial ischemia foliDwed by
reperfusion (rep) significantly enhances cardiac release of the potent vaso-
constrictor endothelin (ET). We now examine the association of ET produc-
tion and myocardial blood flow IMBF) in rabbits (n = 14) undergoing 30 min
Df circumflex occlusion and 3 hrs of rep. MBF was measured with radioac-
tive microspheres at baseline, 15 min into occlusion, 1 min, 1 and 3 hrs into
rep. Utilizing molecular biology techniques, ET1 mRNA was measured at 3
hrs and found to be elevated in the central ischemic zone (CIZ) compared to
the non ischemic zone INIZ). In a second study we investigated the effects
of exogenous ETl and PD145065 (an ETA/B receptor antagonist) on infarct
size of rabbits undergoing 30 min of circumflex occlusion and 48 hrs of rep.
Endothelin ETA/B Receptor Antagonist Reduces
Infarct Size: A Novel Therapy for Acute Myocardial
Infarction
JDaD V. VltDla, JDhn HDlsinger, Menryn B. FDrman, Edwin K. JacksDn,
Masatoshi Kawana, ThDmas QuertermDus, John J. Murray. Vanderbilt University,
Nashville, TN; University of Pittsburgh, Pittsburgh, PA
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0.05 63± -14 (64) 67 ± -18 (69) 62 ± -16 (69) 66±-16 (58)
0.10 81 ± -21 (60) 75 ± -21 (70) 74 ± -19 (59) 72 ± -21 (71)
0.20 83 ± -12 (16) 94 ± -23 (4) 79 ± -16 (18) 73 ± 12 (4)
Total 73 ± -19 (140) 72 ± -21 (143) 69±-19(146) 69 ± -19 (133)
There were no significant differences in aPTT results within dosing groups
or the total patient population for the designated time periods. Conclusion:
Unlike heparin, there does not appear to be a circadian variation in anticoag-
ulant response to hirudin in patients with acute myocardial infarction. This
may contribute to the improved stability in aPTIs observed with hirudin and
has potential clinical importance for both bleeding and thrombotic events.
Is there a Circadian Variation in Anticoagulation
Response to Hirudin Following Acute Myocardial
Infarction?
IX, and XI, by suppressing thrombin generation, may be an important goal
for future management of acute coronary syndromes.
6 hr aPTT (sees)
Timothy D. Henry, Richard C. Becker, Christopher P. Cannon, Carolyn H. McCabe,
Joseph Loscalzo, TIMI5 Investigators. Hennepin County Medical Center,
Minneapolis, MN
There is a well-described circadian variation in the occurrence of acute
thrombotic coronary syndromes. Likewise, a circadian variation in anticoag-
ulant response to heparin has been reported with a peak effect between
00:00 and 04:00 and a nadir 08:00 to 12:00 hours. This contributes to vari-
ability in aPTI's and may be clinically important. predisposing to increased
thrombotic events in the morning and bleeding events at night. The reason
for this variation is unclear. TIMI-5 was a pilot trial of hirudin, a specific di-
rect thrombin inhibitor, with t-PA and aspirin in acute myocardial infarction.
To determine if a circadian variation in anticoagulant response to hirudin is
present, we examined aPTI results obtained using Ciba-Corning 512 monitor
every 12 hours during the 5-day constant infusion in 87 patients at 3 different
fixed infusion rates (0.05, 0.10,0.20 mg/kg/hr). Data for aPTIs drawn during
4 time periods are expressed in seconds: mean ± SD (# of aPTIs).
Hemorrhagic Stroke Associated with High aPTTs
Following Thrombolytic Therapy and Heparin or
Hirudin
Cristopher Granger, Frans Van de Wert, Mark Horrigan, Robert Califf,
Lynn WDodlief, Eric TDPDI, GUSTO Iia Investigators. Duke University Med":al Center,
Durham, NC
In GUSTO Ila, 2564 patients with acute coronary syndrome with ST devia-
tiDn and symptoms within 12 hours were randomized to hirudin (0.6 mg/kg
bolus, 0.6 mglkg/hr infusiDn with out adjustment) or IV heparin (5,000 U bo-
lus, 1100 to 1300 U/hr adjusted tD a target aPTF of 60-90 seconds) for 3-5
days. The 26 patients who suffered hemorrhagic stroke, as expected from
previous studies examining risk factors, were older (median age 71 vs 65).
had higher initial systolic blood pressure (142 vs 134 mmHg) and were more
commonly female (42 vs 31 %). Unexpectedly, hemorrhagic stroke patients
weighed more (82 vs 77 kg), which may have reflected weight-adjusted dos-
ing and consequent administration of more anticoagulant. Of the 26 patients,
23 were treated with thrombolytic therapy. In spite of concern over renal
dysfunction contributing to increased risk, the baseline and 48 hour creati-
nine was similar among hirudin treated patients with (1.2,1.21 and without
(1.1,1.1) hemorrhagic stroke. APTT was a predictor of hemorrhagic stroke,
particularly in the hirudin assigned group:
Multivariable analysis will help to determine the relative importance of risk
factors in GUSTO lIa for hemorrhagic stroke, and whether the elevated aPTTs
appear to fully explain the increased risk. These data illustrate the narroW
therapeutic window for antithrombin therapy in conjuction with thromboly-
sis.
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1989-571Dru~ infusion started with an initial bolus (PD145065 3 mglkg; n ~ 10 or ETl
10- 0m/kg; n ~ 9) 10 min before occlusion followed by 10-11 m/kg/min of
ET1 or 0.6 mglkg/min of PD145065 for 2 hrs and 40 minutes. Control an-
imals (n ~ 10) received the same volumes in saline. Infarct size (AN) was
measured histologically and expressed as percentage of area at risk (AR).
Results as Mean ± SEM.
Increased Plasma Soluble Intercellular Adhesion
Molecule-1 (sICAM-1) Levels in Coronary
Circulation in Patients with Unstable Angina
Hisao Ogawa, Tomohiro Sakamoto, Yuji Miyao. Koich; Kaikita, Hisakazu Suefuji,
Hirofumi Yasue. Kumamoto University. Kumamoto, Japan
To determine whether plasma sICAM-1 levels increase in the coronary circu-
lation in patients (pts) with unstable angina, we measured plasma sICAM-1
levels in the coronary sinus (CS) and aortic root (Ao) simultaneously in 18 un-
stable angina pts (UA), 18 stable exertional angina pts (SEA) and 14 control
pts (Cont). Unstable angina was defined as worsening effort or rest angina.
or both within 1 month of catherization. The three groups were matched for
age and gender. The levels of sICAM-1 were measured by enzyme-linked
immunosorbent assay. Data are shown below as means ± SE Ing/ml).
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Tomohiro Sakamoto, Hisao Ogawa. Hisakazu Suefuji. Koichl Kaikita. NTTKyushu
Hospital and Kumamoto University, Kumamoto, Japan
The mean values of CS and Ao were significantly higher in UA than in SEA
and in Cont. Furthermore. in UA the mean value was higher in CS than in
Ao. There were no significant differences of the mean values of CS and Ao
between SEA and Cont. We conclude that sICAM-1 release is increased es-
pecially in coronary circulation in UA. ICAM-1 is known to be a major ligand
on endothelial cells for adherence of activated leukocyles. These results sug-
gest that activation of leukocytes take place within coronary circulation, fur-
ther may activate platelet and induce coronary thrombosis in UA.
'p < 0.01 vs SEA and Cont, # p < 0.01 vs Ao
The presence of intercellular adhesion molecule-1 (ICAM-1) on arterial en-
dothelial cells and on non-endothelial cells has previously demonstrated in
human coronary atherosclerotic plaques. We hypothesized that ICAM-1 ex-
pression on coronary arteries is increased by mechanical compression of
coronary atherosclerotic plaques such as coronary balloon angioplasty. Coro-
nary thrombolysis (intravenous administration of alteplase. 0.45 mg/kg) was
done in 31 consecutive patients with acute myocardial infarction (AMI) imme-
diately after admission. Thirteen patients whose coronary arteries were not
recanalized completely (below TIMI grade 2) were performed subsequent
coronary angioplasty. Blood sampling were done on admission, 2. 4. 8. 12,
24,48, 72 and 96 hours after admission.
Plasma levels of soluble ICAM-1 were measured by enzyme-linked im-
munosorbent assay. Plasma soluble ICAM-1 level was increased significantly
in patients with angioplasty (p ~ 0.03. vs patients without angioplastyj and
the level reached a peak 8 hours after admission (116 ± 7% of baseline level).
On the other hand. the level was unchanged in patients without angioplasty
(99 ± 3% of baseline. 8 hours after admission).
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Conclusion: Plasma levels of soluble ICAM-1 are increased after angio-
plasty in patients with AMI. Mechanical stimulation of coronary atheroscle-
rotic plaques by balloon catheter may induce activation of mononuclear
leukocyte or T-lymphocyte in the vessel wall. Cytokines released from the
activated leukocyte may amplify the synthesis of ICAM-1 on the endothe-
lium and increase the plasma level of ICAM-1 .
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Serial Changes of Plasma Vitronectin Level in
Patients with Acute Myocardial Infarction:
Possible Role of VN as a Scavenger of
Plasminogen Activator Inhibitor-1
Tomohiro Sakamoto. Hisao Ogawa, Hisakazu Suefuji, Koichi Kaikita. NTTKyushu
Hospital and Kumamoto University, Kumamoto. Japan
Conclusions: 1. Myocardial rep after ischemia is associated with marked
reactive hyperemia. This flow decreases significantly in the CIZ at 3 hrs into
rep demonstrating for the first time that the "no-reflow phenomenon" exists
in the rabbit model. 2. ET1 mRNA was elevated in the CIZ at 3 hrs, suggest-
ing a cause-effect relationship between ET1 production and the "no-reflow
phenomenon". 3. Exogenous infusion of ET1 fails to alter infarct size but an-
tagonism of the ETAlB receptors significantly reduces infarct size in rabbits
and this might represent a novel therapy for acute myocardial infarction in
man.
Leukocytes and Adhesion Molecules in Acute
Ischemic Syndromes
Wednesday, March 22, 1995, 9:00 a.m.-11 :00 a.m.
Ernest N. Morial Convention Center, Hall E
Presentation Hour: 9:00 a.m.-1 0:00 a.m.
Vitronectin (VN) is an adhesive glycoprotein that promotes cell adhesion and
spreading and located in mainly extracellular matrix. VN is also known to
regulate the fibrinolytic system by forming complexes with plasminogen ac-
tivator inhibitor (PAI)-1. To elucidate the serial changes of plasma VN level
in association with fibrinolytic capacity in patients with acute myocardial in-
farction (AMI), we measured plasma levels of VN as well as PAl activity. PAI-5
antigen and tissue plasminogen activator (t-PA)-PAI-1 complexes antigen in
20 consecutive AMI patients. All patients were administered alteplase 0.45
mg/kg intravenously for coronary thrombolysis. Blood sampling was done
on admission. 4. 8. 12. 16. 20. 24 and 48 hours; 3. 4. 5. 6 and 7 days after
admission. PAl activity. PAI-1 antigen and t-PA-PAI-1 complexes antigen lev-
els were increased 4 hours after admission (p < 0.01 vs admission) and the
levels maintained higher level during the first 24 hours. On the other hand,
VN levels were increased at 48 hours (p < 0.01 vs admission) and showed
a tendency to be high until 7 days. In contrast to the VN level. PAl activity.
PAI-1 antigen and t-PA-PAI-1 complexes antigen levels were decreased after
48 hours (p < 0.05 vs 4 hours). We conclude that VN is increased 48 hours
after admission with complementary decreasing of PAI-1 in AMI patients. It
is possible that VN removes PAI-1 from the circulation to the extracellular
matrix where VN exists by forming the complexes. These results suggest
that VN may act as a scavenger of PAI-l and playa protective role for the
fibrinolytic system in patients with AM I.
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